Nothing said here yet.
to join the conversation.
Key TakeawaysIovance shares fell another 11% today after Baird cut its price target to $9 from $11, a day after a 35% drop on updated lung cancer data. The trial’s 24.
Iovance Biotherapeutics (NasdaqGM: IOVA) reported updated positive Phase 2 lifileucel data in metastatic non-small cell lung cancer. A biomarker-enriched subgroup of mNSCLC patients showed a high response rate to lifileucel, according to the new readout.
For questions about this article or underlying research, email [email protected].
Virginia Retirement Systems raised its stakes in all three stocks, with combined holdings worth nearly $3 million at September-end.
Iovance stock crashed Thursday, undercutting its 50-day line, on new durability questions for its experimental lung cancer treatment.
Key TakeawaysIovance Biotherapeutics shares fell 31% after updated lung cancer data showed a 24. 6% response rate in 69 patients, in line with earlier results.
Iovance Biotherapeutics (NASDAQ:IOVA) reported updated data from its registrational IOV-LUN-202 trial of lifileucel in previously treated, non-squamous metastatic non-small cell lung cancer, outlining plans for a supplemental Biologics License Application…
Iovance reported updated results from its Phase 2 IOV-LUN-202 trial evaluating Lifileucel in patients with metastatic non-squamous non-small-cell lung cancer.
Iovance Biotherapeutics (IOVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investing.com -- Shares of Iovance Biotherapeutics (NASDAQ: IOVA) initially dropped 15% before recovering to a 6% loss on Thursday after the company shared updated trial results for its lung cancer therapy, lifileucel.
For questions about this article or underlying research, email [email protected].